Moderna 177% after initial melanoma results showed its personalized vaccine with Merc

Moderna surged 177% after initial melanoma results showed its personalized vaccine with Merck's Keytruda outperformed Keytruda alone in recurrence-free and metastasis-free survival. The companies did not disclose the duration of that benefit or whether patients lived longer overall.